

I

wherein the substituents are described in claim 1, or if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts.

5. A compound according to any one of claims 1 to 3 for use as therapeutically active substance.

6. A pharmaceutical composition comprising at least one of the compounds according to any one of claims 1 to 3 as well as its pharmaceutically acceptable salt.

7. A compound of any one of claims 1 to 3, when applicable as mixtures of enantiomers, diastereomers, or in enantiomerically pure form; as well as its pharmaceutically acceptable salt, for use as a medicament.

8. The use of a compound according to any one of claims 1 to 3 as well as its pharmaceutically acceptable salt for the manufacture of a medicament for the treatment or prevention of diseases relating to allosteric modulators of $mGluR^5$ receptors.

9. The use of a compound according to claim 8 for the treatment or prevention of schizophrenia, cognitive diseases, fragile X syndrome or autism.

10. A compound according to any one of claims 1 to 3 for the treatment or prevention of schizophrenia, cognitive diseases, fragile X syndrome or autism.

11. A method for the treatment of schizophrenia, cognitive diseases, fragile X syndrome or autism, which method comprises administering an effective amount of a compound as defined in any one of claims 1 to 3.

~~12. The invention as hereinbefore described.~~